AR076505A1 - Uso de alopurinol para el tratamiento de la reaccion cutanea en manos -pies - Google Patents

Uso de alopurinol para el tratamiento de la reaccion cutanea en manos -pies

Info

Publication number
AR076505A1
AR076505A1 ARP100101462A ARP100101462A AR076505A1 AR 076505 A1 AR076505 A1 AR 076505A1 AR P100101462 A ARP100101462 A AR P100101462A AR P100101462 A ARP100101462 A AR P100101462A AR 076505 A1 AR076505 A1 AR 076505A1
Authority
AR
Argentina
Prior art keywords
feet
treatment
alopurinol
hands
cutaneous reaction
Prior art date
Application number
ARP100101462A
Other languages
English (en)
Spanish (es)
Inventor
Yolanda Rodemer
Original Assignee
Nobera Pharma Sl
Advancell Advanced In Vitro Cell Technologies S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nobera Pharma Sl, Advancell Advanced In Vitro Cell Technologies S A filed Critical Nobera Pharma Sl
Publication of AR076505A1 publication Critical patent/AR076505A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/12Keratolytics, e.g. wart or anti-corn preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP100101462A 2009-04-29 2010-04-30 Uso de alopurinol para el tratamiento de la reaccion cutanea en manos -pies AR076505A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21489409P 2009-04-29 2009-04-29
EP09382058A EP2246057A1 (en) 2009-04-29 2009-04-29 Use of allopurinol for the treatment of hand foot skin reaction

Publications (1)

Publication Number Publication Date
AR076505A1 true AR076505A1 (es) 2011-06-15

Family

ID=40897536

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100101462A AR076505A1 (es) 2009-04-29 2010-04-30 Uso de alopurinol para el tratamiento de la reaccion cutanea en manos -pies

Country Status (22)

Country Link
US (2) US8623878B2 (cg-RX-API-DMAC7.html)
EP (2) EP2246057A1 (cg-RX-API-DMAC7.html)
JP (1) JP6007101B2 (cg-RX-API-DMAC7.html)
KR (1) KR20120049848A (cg-RX-API-DMAC7.html)
CN (1) CN102421436B (cg-RX-API-DMAC7.html)
AR (1) AR076505A1 (cg-RX-API-DMAC7.html)
AU (2) AU2010243594A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI1011971A2 (cg-RX-API-DMAC7.html)
CA (1) CA2759085C (cg-RX-API-DMAC7.html)
DK (1) DK2424538T3 (cg-RX-API-DMAC7.html)
ES (1) ES2434366T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20131070T1 (cg-RX-API-DMAC7.html)
IL (1) IL215831A (cg-RX-API-DMAC7.html)
ME (1) ME01567B (cg-RX-API-DMAC7.html)
MX (1) MX2011011529A (cg-RX-API-DMAC7.html)
NZ (1) NZ595901A (cg-RX-API-DMAC7.html)
PL (1) PL2424538T3 (cg-RX-API-DMAC7.html)
PT (1) PT2424538E (cg-RX-API-DMAC7.html)
RS (1) RS53005B (cg-RX-API-DMAC7.html)
RU (1) RU2543325C2 (cg-RX-API-DMAC7.html)
SI (1) SI2424538T1 (cg-RX-API-DMAC7.html)
WO (1) WO2010125143A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9220713B2 (en) 2009-10-16 2015-12-29 Duke University Compositions and methods for the treatment of drug-induced hand-foot syndrome
JP2014502998A (ja) * 2011-01-18 2014-02-06 ビカス セラピューティクス,エルエルシー 薬学的組成物ならびに薬学的組成物を作製および使用するための方法
JP2021506958A (ja) 2017-12-13 2021-02-22 オンクォリティ ファーマシューティカルズ チャイナ エルティーディーOnquality Pharmaceuticals China Ltd. Egfr阻害に関連する疾患を予防又は治療する方法
WO2019201195A1 (zh) 2018-04-16 2019-10-24 上海岸阔医药科技有限公司 预防或治疗肿瘤疗法副作用的方法
US20200046703A1 (en) * 2018-08-09 2020-02-13 Asymmetric Therapeutics, Llc Compositions and methods for treatment of the side-effects associated with administration of therapeutic agents
CA3242908A1 (en) 2022-01-05 2023-07-13 Asymmetric Therapeutics, Llc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROLIFERATIVE SKIN DISORDERS AND OTHER SKIN CONDITIONS
KR20250056445A (ko) * 2023-10-19 2025-04-28 (주) 수파드엘릭사 수족증후군 또는 수족피부반응의 예방 또는 치료용 약학 조성물

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0278040B1 (de) 1987-02-13 1991-08-14 Pharm-Allergan Gmbh Verwendung von Pteridinen und/oder Purinen oder eines Xanthinoxidase-Hemmers zur Herstellung eines Arzneimittels zur Behandlung von genetisch bedingten degenerativen Netzhauterkrankungen
GB9218711D0 (en) 1992-09-04 1992-10-21 Salim Aws S M Skin cancer treatment
AU4974893A (en) 1992-09-04 1994-03-29 Aws Shakir Mustafa Salim Skin treatment compositions containing dimethylsulphone and allopurinol or oxypurinol
JP3106817B2 (ja) 1993-11-02 2000-11-06 富士電機株式会社 漏電遮断器
US6284234B1 (en) 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
US6060083A (en) 1999-04-01 2000-05-09 Topical Technologies, Inc. Topical DMSO treatment for palmar-plantar erythrodysethesia
GB0013346D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
DE60117043T2 (de) 2000-11-22 2006-07-13 Rxkinetix, Inc., Louisville Behandlung von mukositis
US7544348B2 (en) 2001-02-15 2009-06-09 Access Pharmaceuticals, Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders
SE0100873D0 (sv) * 2001-03-13 2001-03-13 Astrazeneca Ab Method of treatment
ATE429947T1 (de) 2001-08-29 2009-05-15 Pharmakodex Ltd Vorrichtung zur topischen verabreichung
KR100949318B1 (ko) 2001-11-29 2010-03-23 사운드 파마슈티칼스 인코퍼레이티드 화학요법의 바람직하지 않은 작용을 개선하기 위한 방법과조성물
DE10200578A1 (de) 2002-01-09 2003-07-10 Roehm Gmbh Haft- und Bindemittel für dermale oder transdermale Therapiesysteme
US6979688B2 (en) 2002-02-12 2005-12-27 Ford John P Treatment method against side-effects of chemotherapy
US20040214215A1 (en) 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
EP1631146A4 (en) 2003-06-11 2006-12-06 Novacea Inc TREATMENT OF CANCER USING ACTIVE VITAMIN COMPOUNDS ASSOCIATED WITH RADIOTHERAPEUTIC AGENTS AND TREATMENTS
EP1631297A4 (en) 2003-06-11 2007-09-05 Novacea Inc TREATMENT OF IMMUNOSTIC DISEASES WITH ACTIVE VITAMIN D COMPOUNDS ALONE OR IN COMBINATION WITH OTHER THERAPEUTICS
US20050148907A1 (en) 2003-12-24 2005-07-07 Gregory Skover Treatment of skin using a benefit agent and an apparatus
JP4405326B2 (ja) 2004-06-28 2010-01-27 株式会社東芝 ランドリー機器
PT1796660T (pt) 2004-09-17 2017-02-13 Biomas Ltd Utilização de tricloro(dioxietileno-o,o¿)telurato de amónio (as101) para a inibição da enzima de conversão da interleucina-1 beta
DE602007004849D1 (de) 2006-06-01 2010-04-01 Nobera Pharma Sl Verwendung von allopurinol zur behandlung von palmarer/plantarer erythrodysästhesie

Also Published As

Publication number Publication date
AU2016228193A1 (en) 2016-11-03
CA2759085C (en) 2016-08-16
US8623878B2 (en) 2014-01-07
PL2424538T3 (pl) 2014-05-30
CN102421436A (zh) 2012-04-18
CN102421436B (zh) 2014-05-07
BRPI1011971A2 (pt) 2016-04-26
IL215831A (en) 2016-02-29
IL215831A0 (en) 2012-01-31
US20140080845A1 (en) 2014-03-20
EP2246057A1 (en) 2010-11-03
JP2012525358A (ja) 2012-10-22
MX2011011529A (es) 2012-02-08
ME01567B (me) 2014-04-20
EP2424538A1 (en) 2012-03-07
RS53005B (sr) 2014-04-30
DK2424538T3 (da) 2013-11-04
ES2434366T3 (es) 2013-12-16
JP6007101B2 (ja) 2016-10-12
HK1168042A1 (en) 2012-12-21
EP2424538B1 (en) 2013-08-14
SI2424538T1 (sl) 2013-12-31
HRP20131070T1 (hr) 2013-12-20
PT2424538E (pt) 2013-11-07
NZ595901A (en) 2013-11-29
AU2010243594A1 (en) 2011-11-10
CA2759085A1 (en) 2010-11-04
WO2010125143A1 (en) 2010-11-04
RU2011148355A (ru) 2013-06-10
RU2543325C2 (ru) 2015-02-27
US20100280051A1 (en) 2010-11-04
KR20120049848A (ko) 2012-05-17

Similar Documents

Publication Publication Date Title
AR124134A2 (es) Formulación de uso tópico para un inhibidor de jak
MX2024010140A (es) Nuevos metodos.
SV2011003939A (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
AR076505A1 (es) Uso de alopurinol para el tratamiento de la reaccion cutanea en manos -pies
UY35586A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
AR090349A1 (es) Terapia de combinacion para trastornos proliferativos, kit y uso
CL2011000710A1 (es) Combinacion farmaceutica que comprende un inhibidor especifico de smoothened y un inhibidor de cinasa pi3 especifico; y uso en el tratamiento de cancer.
CY1110336T1 (el) Χρηση της αλλοπουρινολης για τη θεραπεια της παλαμοπελματικης ερυθροδυσαισθησιας
BR112015007366A2 (pt) derivados de acilaminopirimidina para o tratamento de infecções virais e outras doenças
HRP20171648T1 (hr) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
BR112012027197A2 (pt) combinação ou composição farmacêutica, seu uso, kit, e compostos para tratamento de doenças oncológicas e fibróticas
WO2014027975A3 (en) Novel orally administered pharmaceutical formulations
RU2018135973A (ru) Фармацевтическая комбинация, содержащая метроформин и дигидрокверценин, и ее применение для лечения рака
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
CO7101244A2 (es) Fenilimidazopirazoles sustituidos y su uso
AR086800A1 (es) Composicion farmaceutica oftalmologica topica que contiene regorafenib
ECSP10010553A (es) Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre
ECSP077843A (es) Tratamiento o prevención del prurito
CL2010001577A1 (es) Uso de nifurtimox para preparar un medicamento util en el tratamiento de enfermedades causadas por giardias.
AR108792A1 (es) Composiciones que comprenden timolol
PH12013501638A1 (en) (5s,8s)-3-(4`-chlor-3`-fluor-4-methlybiphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one (compound a) for treatment
UY32985A (es) Uso de celivarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administracion de celivarona
CU20100004A7 (es) Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k

Legal Events

Date Code Title Description
FB Suspension of granting procedure